Despite its central role in human cancer MYC deregulation is insufficient by itself to transform cells. Since inherent mechanisms of neoplastic control prevent precancerous lesions from becoming fully malignant, identifying transforming alleles of MYC that bypass such controls may provide fundamental insights into tumorigenesis. To date, the only activated allele of MYC known is T58A, the study of which led to identification of the tumor suppressor FBXW7 and its regulator USP28 as a novel therapeutic target. In this study, we screened a panel of MYC phosphorylation mutants for their ability to promote anchorage-independent colony growth of human MCF10A mammary epithelial cells, identifying S71A/S81A and T343A/S344A/S347A/S348A as more potent oncogenic mutants compared to WT MYC. The increased cell transforming activity of these mutants was confirmed in SH-EP neuroblastoma cells and in three-dimensional MCF10A acini. Mechanistic investigations initiated by a genome-wide mRNA expression analysis of MCF10A acini identified 158 genes regulated by the mutant MYC alleles, compared to only 112 genes regulated by both WT and mutant alleles.
Abstract
Despite its central role in human cancer MYC deregulation is insufficient by itself to transform cells. Since inherent mechanisms of neoplastic control prevent precancerous lesions from becoming fully malignant, identifying transforming alleles of MYC that bypass such controls may provide fundamental insights into tumorigenesis. To date, the only activated allele of MYC known is T58A, the study of which led to identification of the tumor suppressor FBXW7 and its regulator USP28 as a novel therapeutic target. In this study, we screened a panel of MYC phosphorylation mutants for their ability to promote anchorage-independent colony growth of human MCF10A mammary epithelial cells, identifying S71A/S81A and T343A/S344A/S347A/S348A as more potent oncogenic mutants compared to WT MYC. The increased cell transforming activity of these mutants was confirmed in SH-EP neuroblastoma cells and in three-dimensional MCF10A acini. Mechanistic investigations initiated by a genome-wide mRNA expression analysis of MCF10A acini identified 158 genes regulated by the mutant MYC alleles, compared to only 112 genes regulated by both WT and mutant alleles.
Transcriptional gain-of-function was a common feature of the mutant alleles, with many additional genes uniquely dysregulated by individual mutant. Our work identifies novel sites of negative regulation in MYC and thus new sites for its therapeutic attack.
Introduction
The c-Myc (MYC) oncoprotein is a prominent contributor to tumorigenesis.
Understanding pathways that both regulate and cooperate with MYC has the potential to identify novel therapeutic strategies to inhibit this oncogene (1) . The powerful anti-tumour effect of both direct (eg. Omomyc) and indirect (eg. JQ1) MYC inhibition have been experimentally reinforced by important recent publications, underscoring the need to better understand the mechanisms both regulating and contributing to MYC-induced transformation (2) (3) (4) (5) . Phosphorylation has been shown to be an important mechanism regulating MYC activity. For example, two phosphorylation sites within MYC homology box I (MBI), threonine 58 (T58) and serine 62 (S62) undergo hierarchical phosphorylation. S62 can be phosphorylated by a number of kinases, including ERK, JNK, CDK1, and DYRK2 (6, 7) . This subsequently promotes T58 phosphorylation by GSK3, leading to ubiquitylation by SCF-FBXW7 and proteasomal degradation of MYC (6, 8) . The significance of these phosphorylation events has been characterized using alanine point mutations. Specifically, the T58A point mutant is more transforming than wild-type (WT) MYC in both cell line and in vivo models, which has been attributed to both an increase in protein stability and decreased apoptosis (8) (9) (10) (11) (12) (13) . Furthermore, a recent report using the MMTV-MYC transgenic model found fewer activating mutations in RAS when T58A was expressed compared to the WT allele (14) , highlighting how gain-of-function phosphorylation mutants of MYC can be used to understand the cooperating pathways contributing to transformation. Clearly, signalling through T58 is an important mechanism to negatively regulate MYC-induced transformation and the T58A gain-of-function mutant has been an important experimental tool to understand signaling regulating MYC activity.
Despite the impact of the T58A mutant, additional gain-of-function MYC phosphorylation mutants have not been identified. This may, in part, be due to the general absence of somatic MYC mutations in human cancers. While direct deregulation of MYC through point mutations is uncommon, understanding MYC regulation through the analysis of signaling mutants is a valuable experimental approach as many signalling pathways upstream of MYC are altered in cancers. A number of MYC phosphorylation sites have been identified through two-dimensional phosphopeptide mapping, yet the majority have not been functionally characterized (15) (16) (17) . There are four described phosphorylation sites in the N-terminus of MYC including T58,S62, S71 and S81. Two additional clusters of residues have also been identified: T247/T248/S249/S250/S252 and T343/S344/S347/S348 and a single site at S293. S71 can be phosphorylated by JNK to promote MYC-induced apoptosis (9, 18) . Both clusters of phosphorylation sites between amino acids 247-252 and 343-348 have been shown to be targets of casein kinase 2 (CK2) (17) , but to the best of our knowledge there have been no reports establishing a biological role for signalling through these residues.
Herein, we assign biological activity to these sites by conducting a thorough evaluation of these phosphorylation mutants on MYC-induced transformation. We have identified two mutants that demonstrate a gain of transformation compared to WT MYC: the double S71A/S81A mutant and the phosphorylation cluster mutant T343A/S344A/S347A/S348A (MYC-4A). Further investigation into regulation of these phospho-sites may provide new opportunities for therapeutic targeting of cancers with deregulated MYC. 
Materials and Methods

Cell lines
MCF10A and SH-EP cells were cultured as described previously (13, 19) .
Soft agar colony formation
Transformation was evaluated by anchorage-independent colony growth in soft agar using standard protocols, and as previously described (13) . Colony formation was imaged at 1.6x magnification on a Leica Stereomicroscope (Leica MZ FLIII). Colony number and average colony size were quantified with ImageJ software (NIH). For the combined statistical analysis of both colony number and size, as presented in Figure 1C and D, Euclidean distance from c(0,0) to each data point was calculated and a subsequent paired t-test analysis between the Euclidean distances for each mutant against the Euclidean distances for MYC was conducted.
MYC ChIP-on-chip and ChIP-qPCR
MYC ChIP experiments were conducted as previously described (20) . Briefly, 10 7 cells were used per ChIP reaction with each 1.5 μg normal rabbit IgG (Santa Cruz Biotechnology sc-2027) or home-made purified and validated rabbit polyclonal N262. WGA amplified DNA (4 μg) was hybridized to Agilent 2x244 promoter arrays at the UHN microarray center (Toronto, Canada). ChIP-on-chip data was analyzed as described previously (8) . Raw array data are publically available through GEO (GSE13749, GSE14263, GSE14264).
MCF10A 3D morphogenesis
MCF10A acini formation assays were completed as previously described (2) . Morphogenesis was monitored and acini formation was imaged on an AxioObserver microscope at 5x magnification. 
Expression profiling
Oxygen consumption assays
Assays were conducted using a Seahorse Bioscience XF96 instrument using standard protocols.
For each biological replicate the basal oxygen consumption rate (OCR) was measured at 3 time points for triplicate wells, averaged, and normalized to DNA content (CyQuantNF, Invitrogen) from a parallel plate.
For full Materials and Methods please see supporting supplementary material.
Results
MYC phosphorylation mutants increase anchorage-independent growth of MCF10A and
SH-EP cells in soft agar
We first constructed a panel of MYC phosphorylation mutants by substituting serine and threonine residues for alanines. Given the requirement of phosphorylation at S62 for the subsequent phosphorylation of T58 and the knowledge that certain kinases can phosphorylate more than one residue within the N-terminus of MYC, we generated a panel of T58, S62, S71 and S81 mutants that contained every possible combination of these four N-terminal phosphorylation sites mutated to alanine (15, 18) . As clusters of phosphorylation sites have been shown to be phosphorylated by the same kinase (21, 22) a consequence of net charge rather than by the traditional site-specific manner (23), we created single mutants in which all five phosphorylation sites around amino acid 240 (MYC-5A) and all four phosphorylation sites near amino acid 340 (MYC-4A) were mutated to alanines ( Figure   1A ). We also generated the single S293A mutant. In total, our panel contained 18 phosphorylation site mutants.
We evaluated our mutant panel by stable overexpression in non-transformed MCF10A mammary epithelial cells, as we have shown that expression of WT MYC alone is sufficient to promote anchorage-independent colony growth, which is further potentiated by the T58A point mutant (13) When both colony number and colony size were considered and compared to WT MYC, the T58A, S71A/S81A and MYC-4A mutant were all significantly more transforming (p<0.05, Figure 1C ). Combined, these results suggest that signalling through these residues negatively regulates MYC-induced transformation of MCF10A cells.
We next evaluated if these results could be generalized beyond a single cell line model.
We therefore evaluated these gain-of-function mutants in SH-EP neuroblastoma cells. Like the 
Phosphopeptide identification confirms phosphorylation in vivo
To confirm phosphorylation of these sites in vivo, we identified Myc phosphopeptides using mass spectrometry. Briefly, 293Tv cells were transiently transfected with a MYC expression plasmid, MYC protein was immunoprecipitated and subjected to trypsin digestion.
Phosphopeptides were enriched using titanium dioxide (TiO 2 ) or iron-based immobilized metal affinity chromatography (IMAC) material and subjected to mass spectrometry analysis. Several putative serine and threonine phosphorylation sites were identified in tryptic peptides containing amino acids 343-348, including peptides phosphorylated at a single site or at multiple residues Table S1 ). We further identified a peptide in multiple runs that contained a phosphorylation site on one of S67 or S71. We were, however, unable to assign the specific residue from the spectra. Phosphorylation of S71 has also been independently identified in two other studies (24, 25) . Our analysis also identified peptides phosphorylated at S293. Together, these findings independently validate the identity of the previous MYC 2D phosphopeptide mapping studies (15) (16) (17) .
MYC phosphorylation mutants do not alter MYC protein stability
To better understand the mechanisms of how our two phosphorylation mutants could be contributing to enhanced oncogenic activity, we evaluated MYC protein stability.
Cycloheximide experiments revealed that the half-life of both the S71A/S81A and MYC-4A mutants was comparable to both endogenous and ectopic WT MYC, at approximately 30 minutes (Supplementary Figure S3) . Consistent with previous reports in other cell systems, the T58A point mutation increased MYC protein half-life from 30 to 60 minutes (26) (27) (28) . These data suggest that the mechanism(s) responsible for the gain-of-function activity of S71A/S81A and MYC-4A mutants are independent of changes to MYC protein stability and signalling through T58.
Ectopic expression of MYC does not robustly alter the genome-wide binding profile in
MCF10A cells
To begin to understand the downstream mechanisms contributing to MYC-induced Table S2 ). Volcano plots representing the by probe fold change in binding from MYC ChIP compared to IgG control are presented in Figure 2A . Remarkably, genome-wide binding sites were very consistent between endogenous and ectopic Myc ( Figure   2B ), suggesting that MYC-induced transformation is not mediated by an altered promoterbinding profile in these cells.
MAX-interaction and binding to candidate promoters is not altered with MYC phosphorylation mutants
Next, we tested the relative ability of ectopic WT and mutant MYC to interact with MAX and bind candidate promoters. Specifically, the proximity of the MYC-4A residues to the B-HLH domain of MYC suggests these interactions might be especially susceptible to changes in post-translational modifications. Indeed, a previous study has demonstrated that PAK2 phosphorylation of residues within the B-HLH domains regulate both MAX and DNA binding (29) . To address this question it was important to evaluate these parameters with minimal contributions from endogenous MYC. We therefore serum starved MCF10A cells for 2 hours prior to harvest, which depletes endogenous MYC expression and allows us to more effectively compare mutant vs ectopic WT MYC (see GFP input lane 1, Figure 2C , and Supplementary Figure S4 ). MYC and all MYC mutants robustly and comparably bind MAX by coimmunoprecipitation ( Figure 2C ). Additionally, WT and all phosphorylation mutants bound a subset of candidate MYC target genes, both activated (CAD, APEX) and repressed (CDKN1B, SERPINE1), to similar extents as assayed by ChIP-qPCR ( Figure 2D ). The negative controls for this experiment were an exonic E-box within the HNT gene on chromosome 11 (HNT) and nongenic, non-E-box on chromosome 6 (Ch6). Combined these data suggest that the mechanisms of increased transformation of these mutants are not mediated through an increased ability to bind MAX or DNA.
MYC phosphorylation mutants disrupt 3D morphogenesis of MCF10A acini
Growing MCF10As on a bed of extracellular matrix (matrigel) allows cells to form polarized acinar structures that have many of the same characteristics of normal breast tissues in vivo (19) . Overexpression of oncogenes, such as ERBB2, has been shown to disrupt the normal morphogenesis of MCF10A cells in 3D culture (19) , and this model has advanced our ability to study early events in breast tumorigenesis. We cultured MCF10A cells with stable overexpression of the phosphorylation mutant panel on matrigel and evaluated morphogenesis.
Cells with constitutive overexpression of MYC formed phenotypically normal acini, indistinguishable from cells expressing empty vector control ( Figure 3A,B) . This contrasts with a previous report suggesting that overexpression of MYC alone is sufficient to transform MCF10A acini (30) , which may be a reflection of relative levels of ectopic MYC expression. In our system, the level of ectopic MYC expression is similar to that of endogenous MYC in asynchronously growing GFP control cells (Supplementary Figure 1A) (13) . We further characterized MYC levels at different time points after seeding on matrigel. To control for degradation of the highly labile MYC protein we conducted denatured immunoprecipitation to enrich for MYC, then visualized expression by immunoblotting and compared levels of expression relative to DNA content. These experiments show that both endogenous and ectopic MYC protein expression is high on day 4 in culture, but is similarly decreased on day 8
(Supplementary Figure S4 ). These data demonstrate that both endogenous and ectopic MYC proteins are expressed at comparable levels and are similarly regulated through morphogenesis 
of MCF10A cells, as previously described (Supplementary Figure S5) (30) . In cells overexpressing the T58A point mutant, which increases MYC protein stability and further deregulates MYC, there was robust and significant transformation of acini, including the formation of large multi-acinar structures ( Figure 3A, B) . The S71A/S81A and MYC-4A mutants both significantly and effectively promoted transformation of MCF10A acini, with the S71A/S81A mutant showing slightly more transformation than T58A itself ( Figure 3A, B) .
Expression profiling reveals gene expression changes downstream of deregulated MYC
With three MYC gain-of-function alleles, we were in a unique position to interrogate the molecular events associated with MYC-induced transformation of MCF10A acini. RNA was isolated from three independent biological replicates on day 4 of 3D culture, a time point with comparable protein expression and prior to robust morphological differences (Supplementary 
To understand the mechanisms contributing to MYC-induced transformation by the phosphorylation mutants, we conducted Gene Ontology (GO) term enrichment analysis on the significant gene expression changes (Table 2, Supplementary Table S4 ). The most significant GO terms enriched with the S71A/S81A point mutant include those related to DNA synthesis and cell cycle progression ( Table 2, Supplementary Table S4 ), suggesting that these residues might be important for negatively regulating cell-cycle control. Two of the top four most significantly enriched terms for the MYC-4A mutant were non-coding RNA processing and metabolism ( Table 2, Supplementary Table S4 ). These results suggest interesting avenues for further research regarding transforming mechanisms of MYC.
Gene expression profiling reveals a core subset of gene expression changes
Comparing the gene expression changes amongst all MYC alleles was also informative. GO term enrichment analysis of both the common (112 genes) and phosphorylation mutant-specific (158 genes), as well as combined (270 genes) subsets revealed significant enrichment in a number of terms, including those involved in glutamine metabolism and purine and pyrimidine synthesis and metabolism which are consistent with known functions of MYC ( Figure 4B , Table 3 & Supplementary Table S9 ). There were also terms associated with cellmatrix attachment, epithelial morphogenesis, and epithelial to mesenchymal transition, processes that are fundamental to this culture system. We next used these data to ask if the increased transformation exhibited with the phosphorylation mutants was a result of the increased number of gene expression changes, or might also be mediated by a greater change in expression of the common or core subset of 112 genes. Focusing specifically on genes that contributed to the most significantly enriched GO terms, gene expression changes relative to GFP control expressing cells are very similar for WT MYC and the MYC phosphorylation mutants ( Figure 4C ), suggesting that it is the increased number of transcriptional targets regulated by the gain-of-function mutants that is driving the increased cellular transformation.
Deregulated MYC expression increases the oxygen consumption rate in MCF10A cells in 3D culture
Reviewing our gene expression results, there was a common and frequent trend in enriched metabolic pathways. To evaluate cellular metabolism we measured the oxygen consumption rate of MCF10A 3D cultures using a Seahorse Bioanalyzer. We conducted this consumption rate on day 8, relative to GFP cells ( Figure 4D ). These results further support a role for MYC deregulation in altering cell metabolism as a mechanism contributing to cellular transformation.
Discussion
MYC has long been appreciated as a nuclear phosphoprotein, however the functional significance of MYC phosphorylation at a number of residues remains to be established.
Moreover, there have been a surprisingly limited number of studies investigating MYC signalling mutants. It is tempting to speculate that this mirrors the general lack of somatic MYC mutations found in human cancers, an observation that has been confirmed through the abundant tumour sequencing studies now being regularly published (31-34). Of these studies, the tumour type with the most frequent mutations is uterine corpus endometriod carcinomas, with a frequency of only 3.3% (8/240), and all mutations occurring at different residues (34) . Important exceptions to this, however, are Burkitt and AIDS-associated lymphomas, which have been long known to have frequent mutations in MYC exon 2, specifically with a hotspot at T58 (35) (36) (37) .
Intriguingly, while T58 to alanine substitutions are observed in Burkitt lymphomas, the more common mutation is T58I (summarized in (37)), the biological significant of which remains elusive. Through studies of the T58A point mutant, it is clear that studying MYC signaling mutants can be used to uncover and better understand the upstream mechanisms regulating MYC. Our data also suggests that the field may have been challenged by inherent redundancy or the need for cooperating modifications, as the two novel gain-of-function phosphorylation mutants we have characterized are comprised of more than a single amino acid substitution.
While a caveat to our approach is that altering multiple amino acids may alter the overall structure of MYC, especially for the MYC-4A mutant, our mass spectrometry results clearly demonstrate that multiple residues in this cluster simultaneously undergo phosphorylation and structurally altered mutants generally lose, rather than gain, activity. Future studies to understand the interplay or cooperation between these residues, as well as other known sites of MYC post-translational regulation will be important (6, (38) (39) (40) . 
Our MYC:MAX CoIPs and MYC ChIP-qPCR demonstrate that the effect of the MYC phosphorylation mutants is independent of enhanced or altered binding to either MAX or DNA.
The altered transcriptional programs downstream of the phosphorylation mutants therefore suggests that post-translational regulation influences interactions between MYC and other transcriptional cofactors on target genes, and thereby contributes to transcriptional regulation of specific subsets of targets genes. Future work investigating the protein complexes formed both by phosphorylated and unphosphorylated MYC will be instructive. These results can then be extended to genome-wide binding and expression studies for both MYC and the necessary cofactors to advance our understanding of the mechanism of MYC-induced cellular transformation.
Further, as MYC activity is context-dependent, future work to optimize cell isolation from 3D culture for ChIP assays could make this a powerful system to investigate MYC activity alone and in cooperation with other interacting and regulatory proteins.
In conclusion, we have functionally characterized two novel MYC gain-of-function phosphorylation mutants, providing new evidence that the regulation of MYC occurs not only at the level of expression, but can also be directly controlled through signalling events. A better understanding of mechanisms contributing to MYC deregulation and MYC-induced transformation has the potential to identify novel approaches for the therapeutic targeting of MYC activity, either through the inhibition of upstream or downstream pathways. 
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